Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further top five genes viz Rhoa, PI3KCA, CDC42, MAPK3, TP53 were used for Enrichment analysis which revealed their association with vital cellular and functional pathways in prostate cancer indicating their potential as candidate biomarkers in prostate cancer.
|
30937635 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study suggests that miR-93 promoted PC progression and metastasis by repressing DAB2 to activate Akt/ERK1/2 pathway, and elevation of DAB2 and inactivation of Akt/ERK1/2 might be a potential therapeutic target for PC by GTP.
|
30543885 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line.
|
30338032 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings add a new perspective on the role of δ-catenin in enhancing EGFR/Erk1/2 signaling-mediated prostate cancer.
|
29629558 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, all findings here clearly implicated that EGFR-related signal pathways, including EGFR-PI3K-Akt and EGFR-Erk1/2 pathways, were involved in ISO-induced cell growth inhibition and apoptosis in PCa cells, providing a more solid theoretical basis for the application of ISO to treat patients with prostate cancer in clinic.
|
28422286 |
2018 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The chrysin-mediated intracellular signaling pathways suppressed phosphoinositide 3-kinase (PI3K) and the abundance of AKT, P70S6K, S6, and P90RSK proteins, but stimulated mitogen-activated protein kinases (MAPK) and activation of ERK1/2 and P38 proteins in the prostate cancer cells.
|
28213961 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicate that RON and c-Met facilitate metastasis through ERK1/2 signaling and that targeting RON and c-Met with foretinib may be an attractive therapeutic option for suppressing PCa metastasis.
|
28440432 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that coumestrol can inhibit progression of prostate cancer and may be a novel chemotherapeutic agent for treatment of prostate cancer via effects mediated via the PI3K/AKT and ERK1/2 and JNK MAPK cell signaling pathways..
|
27431052 |
2017 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In line with this notion, we show in a xenograft mouse model that prostate cancer cells that are resistant to docetaxel overexpress activated ERK1/2.
|
27692847 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanism underlying the sustained Erk1/2 activation for PCa cell growth inhibition remains unclear.
|
27908592 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we found that PAFR time-dependently induced activation of ERK1/2, and ERK1/2 pathway contributed to PAFR-mediated prostate cancer cell invasion, migration and growth.
|
27176648 |
2016 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that PI3K-C2β regulates mitogen-activated protein kinase kinase (MEK1/2) and extracellular signal-regulated kinase (ERK1/2) activation in prostate cancer (PCa) cells.
|
26983806 |
2016 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sulforaphane inhibits invasion by phosphorylating ERK1/2 to regulate E-cadherin and CD44v6 in human prostate cancer DU145 cells.
|
26134113 |
2015 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, these mitogen-activated protein kinase activities were also triggered by re-expressed E-cadherin leading to p38 and ERK1/2 activity in PCa cells; these signals provide protection to PCa cells upon challenge with chemotherapy and cell death-inducing cytokines.
|
24619413 |
2014 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Such oncogenic-like properties are found in conjunction with a positive regulation of NPM1 on the ERK1/2 (Extracellular signal-Regulated Kinases 1/2) kinase phosphorylation in response to EGF (Epidermal Growth Factor) stimulus, which is critical for prostate cancer progression following the setting of an autonomous production of the growth factor.
|
24796332 |
2014 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, constitutive activation of CXCR4, ERK1/2, and c-Myc signaling was evident in clinical tissue samples from human patients with docetaxel-resistant prostate cancer.
|
23788635 |
2013 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion.
|
23701950 |
2013 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGFA(165) treatment induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in PC3 cells but not in HPV7 cells, suggesting that the autocrine function of VEGFA may be uniquely associated with prostate cancer.
|
22705563 |
2012 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Exogenous administration of a synthetic MGF E peptide stimulated the PCa cell growth and activated ERK1/2 phosphorylation without affecting Akt phosphorylation.
|
20564425 |
2010 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We herein demonstrate that the cross-linking of cell surface PSMA with specific antibodies activates the small GTPases RAS and RAC1 and the MAPKs p38 and ERK1/2 in prostate carcinoma LNCaP cells.
|
19242540 |
2009 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
They exert their action through binding to the cell surface receptor, epidermal growth factor receptor (EGFR), and cause activation of Erk1/2 mediated mitogenic signaling in human prostate cancer (PCA) at both advanced and androgen-independent stages.
|
18253818 |
2008 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced Erk1/2 activation in human prostate cancer PC-3 cells is a paradigm of diacylglycerol-induced EGFR transactivation in androgen-independent prostate cancer.
|
15897236 |
2005 |